Pharmaceutical nanotechnology for oral delivery of anticancer drugs

Advanced Drug Delivery Reviews

Volumn 65, Issue 6, 2013, Pages 880-890

  Mei, Lin ^a   Zhang, Zhiping ^b   Zhao, Lingyun ^a   Huang, Laiqiang ^a   Yang, Xiang Liang ^b   Tang, Jintian ^a   Feng, Si Shen ^c  

^a TSINGHUA UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bioavailability; Biodegradable polymers; Cancer nanotechnology; Chemotherapeutic engineering; Gastrointestinal barrier (GI barrier); Nanomedicine

Indexed keywords

BIOAVAILABILITY; CANCER NANOTECHNOLOGY; CHEMOTHERAPEUTIC ENGINEERING; GASTROINTESTINAL BARRIER (GI BARRIER); MEDICAL COMPLICATIONS; MULTIDRUG EFFLUX; SOLID LIPID NANOPARTICLE (SLN); THERAPEUTIC EFFICACY;

BIOCHEMISTRY; BIODEGRADABLE POLYMERS; CELL MEMBRANES; CHEMOTHERAPY; CYTOLOGY; DENDRIMERS; DRUG DELIVERY; LIPOSOMES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; NANOTECHNOLOGY;

DRUG PRODUCTS;

ANTINEOPLASTIC AGENT; BELINOSTAT; CAPECITABINE; COLCHICINE; CREMOPHOR; CYCLOSPORIN A; DENDRIMER; DOCETAXEL; DOXORUBICIN; EUGENOL; EXCIPIENT; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; LIPOSOME; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; NANOPARTICLE; PACLITAXEL; POLYMER; PRACINOSTAT; PRODRUG; RITONAVIR; ROMIDEPSIN; RUBITECAN; SB 939; SOLID LIPID NANOPARTICLE; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ADHESION; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CUTANEOUS T CELL LYMPHOMA; DIFFUSION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; FIRST PASS EFFECT; GASTROINTESTINAL MUCOSA; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MICELLE; NANOEMULSION; NANOTECHNOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY CANCER; PANCREAS CARCINOMA; PARTICLE SIZE; PERIPHERAL T CELL LYMPHOMA; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; LIPOSOMES; MACROMOLECULAR SUBSTANCES; NANOTECHNOLOGY;

EID: 84878874855     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.11.005     Document Type: Review

References (106)

1. O'Neill V.J., Twelves C.J. Oral cancer treatment: developments in chemotherapy and beyond. Br. J. Cancer 2002, 87:933-937.
2. Feng S.S. Chemotherapeutic: concept, feasibility, safety and prospect - a tribute to Shu Chien's 80th birthday. Cell. Mol. Bioeng. 2011, 4:708-716.
3. Feng S.S., Zhao L.Y., Tang J.T. Nanomedicine for oral chemotherapy. Nanomedicine 2011, 6:407-410.
4. Feng S.S., Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci. 2003, 58:4087-4114.
5. Ten Tije A.J., Verweij J., Loos W.J., Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 2003, 42:665-685.
6. Terwogt J.M.M., Beijnen J.H., Huinink W.W.T., Rosing H., Schellens J.H.M. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 1998, 352:285.
7. Benet L.Z., Izumi T., Zhang Y., Silverman J.A., Wacher V.J. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Control. Release 1999, 62:25-31.
8. Bansal T., Akhtar N., Jaggi M., Khar R.K., Talegaonkar S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov. Today 2009, 14:1067-1074.
9. Malingre M.M., Beijnen J.H., Schellens J.H.M. Oral delivery of taxanes. Invest. New Drugs 2001, 19:155-162.
10. Malingre M.M., Richel D.J., Beijnen J.H., Rosing H., Koopman F.J., Ten Bokkel Huinink W.W., Schot M.E., Schellens J.H. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J. Clin. Oncol. 2001, 19:1160-1166.
11. Malingre M.M., Terwogt J.M.M., Beijnen J.H., Rosing H., Koopman F.J., van Tellingen O., Duchin K., Ten Bokkel Huinink W.W., Swart M., Lieverst J., Schellens J.H.M. Phase I and pharmacokinetic study of oral paclitaxel. J. Clin. Oncol. 2000, 18:2468-2475.
12. Bardelmeijer H.A., Ouwehand M., Buckle T., Huisman M.T., Schellens J.H., Beijnen J.H., van Tellingen O. Low systemic exposure of oral docetaxel in mice resulting from extensive-pass metabolism is boosted by ritonavir. Cancer Res. 2002, 62:6158-6164.
13. Bansal T., Jaggi M., Khar R.K., Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci. 2009, 12:46-78.
14. Buggins T.R., Dickinson P.A., Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv. Drug Deliv. Rev. 2007, 59:1482-1503.
15. Zhang Z., Tan S., Feng S.S. VitaminE TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012, 33:4889-4906.
16. Dintaman J.M., Silverman J.A. Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. 1999, 16:1550-1556.
17. Yu L., Bridgers A., Polli J., Vicker A., Long S., Roy A., Winnike R., Coffin M. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm. Res. 1999, 16:1812-1817.
18. Lo Y.L. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control. Release 2003, 90:37-48.
19. Batrakova E.V., Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Release 2008, 130:98-106.
20. Arima H., Yunomae K., Hirayama F., Uekama K. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. J. Pharmacol. Exp. Ther. 2001, 297:547-555.
21. Ishikawa M., Yoshii H., Furuta T. Interaction of modified cyclodextrins with cytochrome P-450. Biosci. Biotechnol. Biochem. 2005, 69:246-248.
22. Dong Y.C., Feng S.S. Nanoparticles of montmorillonite (MMT)/Poly (d, l-lactide-co-glycolide) (PLGA) for oral delivery of anticancer drugs. Biomaterials 2005, 26:6068-6076.
23. Feng S.S., Mei L., Anitha P., Gan C.W., Zhou W.Y. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of docetaxel. Biomaterials 2009, 30:3297-3306.
24. DeMario M.D., Ratain M.J. Oral chemotherapy: rationale and future directions. J. Clin. Oncol. 1998, 16:2557-2567.
25. Feng S.S. Nanomedicine: nanoparticles of biodegradable polymers for cancer diagnosis and treatment. Cosmos 2008, 4:185-201.
26. Feng S.S. New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?. Nanomedicine 2006, 1:297-309.
27. Feng S.S. Nanoparticles of biodegradable polymers for new concept chemotherapy. Expert. Rev. Med. Dev. 2004, 1:115-125.
28. Feng S.S., Mu L., Win K.Y., Huang G.F. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. 2004, 11:413-424.
29. Ensign L.M., Cone R., Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 2012, 64:557-570.
30. Goldberg M., Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat. Rev Drug Discov. 2003, 2:289-295.
31. Schenk M., Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Pract. Res. Clin. Gastroenterol. 2008, 22:391-409.
32. Frey A., Giannasca K.T., Weltzin R., Giannasca P.J., Reggio H., Lencer W.I., Neutra M.R. Role of the glycocalyx in regulating access of microparticles to apicalplasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J. Exp. Med. 1996, 184:1045-1059.
33. Plapied L., Duhem N., des Rieux A., Preat V. Fate of polymeric nanocarriers for oral drug delivery. Curr. Opin. Colloid Interface 2011, 16:228-237.
34. Sant S., Tao S.L., Fisher O.Z., Xu Q., Peppas N.A., Khademhosseini A. Microfabrication technologies for oral drug delivery. Adv. Drug Deliv. Rev. 2012, 64:496-507.
35. Allémann E., Leroux J., Gurny R. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv. Drug Deliv. Rev. 1998, 34:171-189.
36. Cone R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 2009, 61:75-85.
37. Yang M., Lai S.K., Wang Y.Y., Zhong W.X., Happe C., Zhang M., Fu J., Hanes J. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew. Chem. Int. Ed. 2011, 50:2597-2600.
38. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61:158-171.
39. Suk J.S., Lai S.K., Boylan N.J., Dawson M.R., Boyle M.P., Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine 2011, 6:365-375.
40. Gaumet M., Gurny R., Delie F. Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur. J. Pharm. Sci. 2009, 36:465-473.
41. Norris D.A., Puri N., Sinko P.J. The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug Deliv. Rev. 1998, 34:135-154.
42. Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv. Drug Deliv. Rev. 1998, 34:221-233.
43. Jani P., Halbert G.W., Langridge J., Florence A.T. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 1990, 42:821-826.
44. Win K.Y., Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26:2713-2722.
45. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13:1838-1845.
46. Belting M., Sandgren S., Wittrup A. Nuclear delivery of macromolecules: barriers and carriers. Adv. Drug Deliv. Rev. 2005, 57:505-527.
47. Singh Y., Palombo M., Sinko P.J. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem. 2008, 15:1802-1826.
48. Li F., Maag H., Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J. Pharm. Sci. 2008, 97:1109-1134.
49. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., Shimma N., Umeda I., Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancertissue. Eur. J. Cancer 1998, 34:1274-1281.
50. Walko C.M., Lindley C. Capecitabine: a review. Clin. Ther. 2005, 27:23-44.
51. Novotny-Diermayr V., Sangthongpitag K., Hu C.Y., Wu X., Sausgruber N., Yeo P., Greicius G., Pettersson S., Loh Y.K., Bonday Z., Goh K.C., Hentze H., Hart S., Wang H., Ethirajulu K., Wood J.M. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol. Cancer Ther. 2010, 9:642-652.
52. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
53. Mercurio C., Minucci S., Pelicci P.G. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol. Res. 2010, 62:18-34.
54. Stimson L., Wood V., Khan O., Fotheringham S., La Thangue N.B. HDAC inhibitor-based therapies and haematological malignancy. Ann. Oncol. 2009, 20:1293-1302.
55. Grant C., Rahman F., Piekarz R., Peer C., Frye R., Robey R.W., Gardner E.R., Figg W.D., Bates S.E. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert. Rev. Anticancer. Ther. 2010, 10:997-1008.
56. Jayaraman R., Pilla Reddy V., Pasha M.K., Wang H., Sangthongpitag K., Yeo P., Hu C.Y., Wu X., Xin L., Goh E., New L.S., Ethirajulu K. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab. Dispos. 2011, 39:2219-2232.
57. Wang H., Yu N., Chen D., Lee K.C., Lye P.L., Chang J.W., Deng W., Ng M.C., Lu T., Khoo M.L., Poulsen A., Sangthongpitag K., Wu X., Hu C., Goh K.C., Wang X., Fang L., Goh K.L., Khng H.H., Goh S.K., Yeo P., Liu X., Bonday Z., Wood J.M., Dymock B.W., Kantharaj E., Sun E.T. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J. Med. Chem. 2011, 54:4694-4720.
58. Singh K.K., Vingkar S.K. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int. J. Pharm. 2008, 347:136-143.
59. Nazzal S., Smalyukh I.I., Lavrentovich O.D., Khan M.A. Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation. Int. J. Pharm. 2002, 235:247-265.
60. Cai Z., Wang Y., Zhu L.J., Liu Z.Q. Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr. Drug Metab. 2010, 11:197-207.
61. Gao P., Rush B.D., Pfund W.P., Huang T., Bauer J.M., Morozowich W., Kuo M.S., Hageman M.J. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 2003, 92:2386-2398.
62. Gao P., Akrami A., Alvarez F., Hu J., Li L., Ma C., Surapaneni S. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J. Pharm. Sci. 2009, 98:516-528.
63. Rao S.V., Yajurvedi K., Shao J. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of protein drugs: III. In vivo oral absorption study. Int. J. Pharm. 2008, 362:16-19.
64. Shen Q., Wang Y., Zhang Y. Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer. Int. J. Nanomedicine 2011, 6:1237-1243.
65. Lu J.L., Wang J.C., Zhao S.X., Liu X.Y., Zhao H., Zhang X., Zhou S.F., Zhang Q. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecinon human cancer xenografts in nude mice. Eur. J. Pharm. Biopharm. 2008, 69:899-907.
66. Kaminskas L.M., Porter C.J. Targeting the lymphatics using dendritic polymers (dendrimers). Adv. Drug Deliv. Rev. 2011, 63:890-900.
67. Kaminskas L.M., Boyd B.J., Porter C.J. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine 2011, 6:1063-1084.
68. Jevprasesphant R., Penny J., Attwood D., D'Emanuele A. Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. J. Control. Release 2004, 97:259-267.
69. Wiwattanapatapee R., Carreno-Gomez B., Malik N., Duncan R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system?. Pharm. Res. 2000, 17:991-998.
70. Ke W., Zhao Y., Huang R., Jiang C., Pei Y. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J. Pharm. Sci. 2008, 97:2208-2216.
71. Kitchens K.M., Foraker A.B., Kolhatkar R.B., Swaan P.W., Ghandehari H. Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm. Res. 2007, 24:2138-2145.
72. Najlah M., Freeman S., Attwood D., D'Emanuele A. Synthesis and assessment of first-generation polyamidoamine dendrimer prodrugs to enhance the cellular permeability of P-gp substrates. Bioconjug. Chem. 2007, 18:937-946.
73. Najlah M., Freeman S., Attwood D., D'Emanuele A. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int. J. Pharm. 2007, 336:183-190.
74. D'Emanuele A., Jevprasesphant R., Penny J., Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J. Control. Release 2004, 95:447-453.
75. Gaucher G., Satturwar P., Jones M.C., Furtos A., Leroux J.C. Polymeric micelles for oral drug delivery. Eur. J. Pharm. Biopharm. 2010, 76:147-158.
76. Lee S.C., Huh K.M., Lee J.H., Cho Y.W., Galinsky R.E., Park K. Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization. Biomacromolecules 2007, 8:202-208.
77. Peltier S., Oger J.M., Lagarce F., Couet W., Benoit J.P. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm. Res. 2006, 23:1243-1250.
78. Li H., Huo M., Zhou J., Dai Y., Deng Y., Shi X., Masoud J. Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. J. Pharm. Sci. 2010, 99:4543-4553.
79. Mo R., Jin X., Li N., Ju C., Sun M., Zhang C., Ping Q. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles. Biomaterials 2011, 32:4609-4620.
80. Mathot F., van Beijsterveldt L., Preat V., Brewster M., Arien A. Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J. Control. Release 2006, 111:47-55.
81. Mathot F., des Rieux A., Ariën A., Schneider Y.J., Brewster M., Préat V. Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier. J. Control. Release 2007, 124:134-143.
82. Chiang C.M., Weiner N. Gastrointestinal uptake of liposomes. II. In vivo studies. Int. J. Pharm. 1987, 40:143-150.
83. Ryan C.W., Fleming G.F., Janisch L., Ratain M.J. A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am. J Clin. Oncol. 2000, 23:297-300.
84. Wu J., Liu Q., Lee R.J. A folate receptor-targeted liposomal formulation for paclitaxel. Int. J. Pharm. 2006, 316:148-153.
85. Moutardier V., Tosini F., Vlieghe P., Cara L., Delpero J.R., Clerc T. Colloidal anticancerdrugs bioavailabilities in oral administration models. Int. J. Pharm. 2003, 260:23-38.
86. Chakraborty S., Shukla D., Mishra B., Singh S. Lipid - an emerging platform for oral delivery of drugs with poor bioavailability. Eur. J. Pharm. Biopharm. 2009, 73:1-15.
87. Pouton C.W., Porter C.J.H. Formulation of lipid-based delivery systems for oral administration: materials methods and strategies. Adv. Drug Deliv. Rev. 2008, 60:625-637.
88. Porter C.J.H., Colin W.P., Cuine J.F., Charman W.-N. Enhancing intestinal drug solubilization using lipid-based delivery systems. Adv. Drug Deliv. Rev. 2008, 60:673-691.
89. Trevaskis N.L., Charman W.N., Porter C.J.H. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv. Drug Deliv. Rev. 2008, 60:702-716.
90. Muller R.H., Ruhl D., Runge S., Schulze-Forster K., Wolfgang M. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 1997, 14:458-462.
91. Roger E., Lagarce F., Garcion E., Benoit J.P. Biopharmaceutical parameters to consider inorder to alter the fate of nanocarriers after oral delivery. Nanomedicine 2010, 5:287-306.
92. Roger E., Lagarce F., Garcion E., Benoit J.P. Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. Eur. J. Pharm. Sci. 2010, 40:422-429.
93. Liu D., Liu C., Zou W., Zhang N. Enhanced gastrointestinal absorption of N3-O-toluyl-fluorouracil by cationic solid lipid nanoparticles. J. Nanopart. Res. 2010, 12:975-984.
94. Youk H.J., Lee E., Choi M.K., Lee Y.J., Chung J.H., Kim S.H., Lee C.H., Lim S.J. Enhanced anticancer efficacy of alpha-tocopheryl succinate byconjugation with polyethylene glycol. J. Control. Release 2005, 107:43-52.
95. Constantinou C., Papas A., Constantinou A.I. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int. J. Cancer 2008, 123:739-752.
96. Neuzil J., Tomasetti M., Zhao Y., Dong L.F., Birringer M., Wang X.F., Low P., Wu K., Salvatore B.A., Ralph S.J. Vitamin E analogs a novel group of "mitocans", asanticancer agents: the importance of being redox-silent. Mol. Pharmacol. 2007, 71:1185-1199.
97. Feng S.S., Zhao L.Y., Zhang Z.P., Bhakta G., Win K.Y., Dong Y.C., Chien S. Chemotherapeutic engineering: Vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168hours in vivo. Chem. Eng. Sci. 2007, 62:6641-6648.
98. Zhang Z.P., Lee S.H., Gan C.W., Feng S.S. Pharmacokinetics, biodistribution and xenograft tumor model of PLA-TPGS nanoparticles prepared by dialysis method for controlled and sustained small molecule chemotherapy. Pharm. Res. 2008, 25:1925-1935.
99. Gan C.W., Chien S., Feng S.S. Enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation. Curr. Pharm. Design 2010, 16:2308-2320.
100. Zhao L.Y., Feng S.S. Enhanced oral bioavailability of paclitaxel with vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J. Pharm. Sci. 2010, 99:3552-3560.
101. D. Dobrozsi, Oral liquid mucoadhesive compositions, US Patent Appl. (2001) No. 10/021,327.
102. Sun B.F., Ranganathan B., Feng S.S. Multifunctional poly(d, l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 2008, 29:475-486.
103. Zabaleta V., Ponchel G., Salman H., Agüeros M., Vauthier C., Irache J.M. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. Eur. J. Pharm. Biopharm. 2012, 81:514-523.
104. Arbos P., Campanero M.A., Arangoa M.A., Renedo M.J., Irache J.M. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J. Control. Release 2003, 89:19-30.
105. Arbos P., Campanero M.A., Arangoa M.A., Irache J.M. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J. Control. Release 2004, 96:55-65.
106. Agueros M., Zabaleta V., Espuelas S., Campanero M.A., Irache J.M. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J. Control. Release 2010, 145:2-8.